Ligand Pharmaceuticals (LGND) EBIT (QoQ) (2010 - 2026)
Ligand Pharmaceuticals (LGND) EBIT (QoQ) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Ligand Pharmaceuticals | 6.05 Bn | 5.27 Bn | 48.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 25.46% |
| Dec 31, 2025 | -74.80% |
| Sep 30, 2025 | 550.53% |
| Jun 30, 2025 | 123.32% |
| Mar 31, 2025 | -275.80% |
| Dec 31, 2024 | -406.62% |
| Sep 30, 2024 | 116.46% |
| Jun 30, 2024 | -739.22% |
| Mar 31, 2024 | 188.98% |
| Dec 31, 2023 | -209.10% |
| Sep 30, 2023 | 255.22% |
| Jun 30, 2023 | -113.96% |
| Mar 31, 2023 | 170.68% |
| Dec 31, 2022 | -262.86% |
| Sep 30, 2022 | 42.47% |
| Jun 30, 2022 | 306.09% |
| Mar 31, 2022 | -94.34% |
| Dec 31, 2021 | 139.97% |
| Sep 30, 2021 | -65.66% |
| Jun 30, 2021 | 870.07% |